Study to Evaluate SPI-1005 in Adults With Meniere's Disease

• ClinicalTrials.gov Identifier: NCT02603081
• Recruitment Status: Completed
• First Posted: November 11, 2015
• Last Update Posted: March 18, 2021
• Sponsor: Sound Pharmaceuticals, Incorporated
• Information provided by (Responsible Party): Sound Pharmaceuticals, Incorporated

Study Description

Brief Summary:

This study will evaluate the safety and efficacy of three dose levels of SPI-1005 compared to placebo on vertigo, tinnitus and sensorineural hearing loss in 40 adults with Meniere's disease.

Condition or disease	Intervention/treatment	Phase
Meniere's Disease	Drug: SPI-1005	Phase 1; Phase 2

Detailed Description:

Randomized, double-blind, placebo-controlled safety, pharmacokinetic, pharmacodynamic study of oral SPI-1005 in adults with Meniere's disease. All subjects will undergo baseline audiometric testing and have their severity of sensorineural hearing loss, tinnitus and vertigo determined before the start of a 21-day course of treatment with SPI-1005 or placebo. During treatment with SPI-1005, and 7 days and 28 days following the cessation of SPI-1005, subjects will have their hearing loss, tinnitus and vertigo assessed. Additional testing including electrocochleography will be performed at baseline, at the end of SPI-1005 treatment, and 28 days after the SPI-1005 treatment has stopped. Six outpatient visits will be performed over a 7-week period.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease
• Study Start Date: December 2015
• Actual Primary Completion Date: August 2017
• Actual Study Completion Date: August 2017

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo; 0 mg SPI-1005 bid po x 21d	Drug: SPI-1005; Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.; Other Name: ebselen
Active Comparator: Low dose; 200 mg SPI-1005 bid po x 21d	Drug: SPI-1005; Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.; Other Name: ebselen
Active Comparator: Mid dose; 400 mg SPI-1005 bid po x 21d	Drug: SPI-1005; Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.; Other Name: ebselen
Active Comparator: High dose; 600 mg SPI-1005 bid po x 21d	Drug: SPI-1005; Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.; Other Name: ebselen

Outcome Measures

Primary Outcome Measures :

1. Safety and tolerability of SPI-1005 using histories, physical exams, and clinical measures. [ Time Frame: 7 weeks ]
   Incidence of of Treatment-Emergent Adverse Events

Secondary Outcome Measures :

1. Plasma Ebselen levels of SPI-1005 before, during, and after 21 days of dosing [ Time Frame: 7 weeks ]
   Evaluation of potential accumulation of study drug
2. Plasma Selenium levels before, during, and after 21 days of dosing [ Time Frame: 7 weeks ]
   Evaluation of potential changes in plasma selenium levels
3. Impact on Sensorineural Hearing Loss [ Time Frame: 7 weeks ]
   Pure Tone Audiometry
4. Impact on Speech Discrimination [ Time Frame: 7 weeks ]
   Words in Noise Test
5. Impact on Tinnitus [ Time Frame: 7 weeks ]
   Questionnaire
6. Impact on Vertigo [ Time Frame: 7 weeks ]
   Questionnaire
7. Pharmacodynamic response [ Time Frame: 7 weeks ]
   Electrocochleography

Eligibility Criteria

• Ages Eligible for Study: 19 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Diagnosis of probable or definite Meniere's Disease by AAO-HNS 1995 criteria within 12 months of study enrollment;
• Voluntarily consent to participate in the study;

• Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods:

  • Sexual abstinence (inactivity) for 14 days prior to screening through study completion; or
  • IUD in place for at least 3 months prior to study through study completion; or
  • Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening through study completion; or
  • Stable hormonal contraceptive for at least 3 months prior to study through study completion; or
  • Surgical sterilization (vasectomy) of partner at least 6 months prior to study.
• Females of non-childbearing potential should be surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be at least 3 years since last menses.

Exclusion Criteria:

• Current use or within 90 days prior to study of ototoxic medications such as aminoglycoside antibiotics (gentamicin, tobramycin, amikacin, streptomycin); platinum-containing chemotherapies (cisplatin, carboplatin, oxaliplatin); or loop diuretic (furosemide);
• History of idiopathic sensorineural hearing loss, otosclerosis, or vestibular schwannoma;
• History of middle ear or inner ear surgery;
• Current conductive hearing loss or middle ear effusion;
• Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, or psychiatric disease;
• History of hypersensitivity or idiosyncratic reaction to compounds related to ebselen;
• Current use or within 30 days prior to study of drugs or substances known to be strong inhibitors or inducers of cytochrome P450 enzymes;
• Participation in another investigational drug or device study within 90 days prior to study enrollment;
• Female patients who are pregnant or breastfeeding.

Contacts and Locations

Locations

United States, California

House Clinic

Los Angeles, California, United States, 90057

United States, New York

New York Otology

New York, New York, United States, 10028

United States, South Carolina

MUSC

Charleston, South Carolina, United States, 29425

United States, Washington

Sound Pharmaceuticals, Inc.

Seattle, Washington, United States, 98103

Northwest Ear

Seattle, Washington, United States, 98104

Sponsors and Collaborators

Sound Pharmaceuticals, Incorporated

Investigators

• Study Chair: Jonathan Kil, MD; Sound Pharmaceuticals

More Information

Publications:

Kil J, Pierce C, Tran H, Gu R, Lynch ED. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res. 2007 Apr;226(1-2):44-51. doi: 10.1016/j.heares.2006.08.006. Epub 2006 Oct 6.

Lynch E, Kil J. Development of ebselen, a glutathione peroxidase mimic, for the prevention and treatment of noise-induced hearing loss. Semin Hear 2009; 30(1):47-55.

Kil J, Harruff EE, Longenecker RJ. Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hear Res. 2022 Jan;413:108209. doi: 10.1016/j.heares.2021.108209. Epub 2021 Feb 19.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Garland M, Hryckowian AJ, Tholen M, Bender KO, Van Treuren WW, Loscher S, Sonnenburg JL, Bogyo M. The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI. Cell Rep Med. 2020 Apr 21;1(1):100005. doi: 10.1016/j.xcrm.2020.100005.

• Responsible Party: Sound Pharmaceuticals, Incorporated
• ClinicalTrials.gov Identifier: NCT02603081
• Other Study ID Numbers: SPI-1005-151
• First Posted: November 11, 2015
• Last Update Posted: March 18, 2021
• Last Verified: March 2021

Keywords provided by Sound Pharmaceuticals, Incorporated:

Meniere's; hearing loss; vertigo; tinnitus; ebselen

Additional relevant MeSH terms:

Meniere Disease; Endolymphatic Hydrops; Labyrinth Diseases; Ear Diseases; Otorhinolaryngologic Diseases; Ebselen; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Inflammatory Agents; Antirheumatic Agents; Anti-Ulcer Agents; Gastrointestinal Agents; Antioxidants; Molecular Mechanisms of Pharmacological Action; Protective Agents; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Neuroprotective Agents